Literature DB >> 11701549

Bone Marrow Transplantation for Non-Malignant Disease.

Keith M. Sullivan, Robertson Parkman, Mark C. Walters.   

Abstract

This article reviews the experience in hematopoietic stem cell transplantation (HSCT) for non-malignant disease. HSCT has long been applied as treatment of life-threatening congenital immunodeficiency and metabolic diseases. In Section I, Dr. Parkman reviews that experience for severe combined immunodeficiency, Wiscott-Aldrich syndrome, hyper IGM syndrome, Chédiak-Higashi disease and hereditary lymphohistiocytosis. The value of HSCT in genetic metabolic diseases such as osteopetrosis, osteogenesis imperfecta and the storage diseases are reviewed. In Section II, Dr. Walters reviews the experience over the last decade with allogeneic stem cell transplantation in patients with thalassemia major and sickle cell disease. In Section III, Dr. Sullivan reviews the more recent investigations using stem cell transplantation in patients with advanced autoimmune diseases such as systemic sclerosis, systemic lupus erythematosus, multiple sclerosis and juvenile rheumatoid arthritis. The pathogenesis and outcome with conventional care of these patients, the selection criteria and current results for HSCT, and the future directions in clinical research and patient care using this modality are addressed.

Entities:  

Year:  2000        PMID: 11701549     DOI: 10.1182/asheducation-2000.1.319

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  8 in total

Review 1.  Bone marrow transplantation for non-malignant disease.

Authors:  Keith M Sullivan
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes.

Authors:  Olivier Joffre; Nathalie Gorsse; Paola Romagnoli; Denis Hudrisier; Joost P M van Meerwijk
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

3.  Bone mass and microarchitecture of irradiated and bone marrow-transplanted mice: influences of the donor strain.

Authors:  A Dumas; M Brigitte; M F Moreau; F Chrétien; M F Baslé; D Chappard
Journal:  Osteoporos Int       Date:  2008-06-12       Impact factor: 4.507

4.  In vivo engineering of bone tissues with hematopoietic functions and mixed chimerism.

Authors:  Yu-Ru Shih; Heemin Kang; Vikram Rao; Yu-Jui Chiu; Seong Keun Kwon; Shyni Varghese
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

Review 5.  Treatment options for juvenile-onset systemic lupus erythematosus.

Authors:  Luis Carreño; Francisco Javier López-Longo; Carlos Manuel González; Indalecio Monteagudo
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Unrelated donor marrow transplantation for congenital immunodeficiency and metabolic disease: an update of the experience of the Japan Marrow Donor Program.

Authors:  Naoki Sakata; Keisei Kawa; Koji Kato; Hiromasa Yabe; Miharu Yabe; Masayuki Nagasawa; Hideo Mugishima; Hisato Kigasawa; Masahiro Tsuchida; Yuichi Akiyama; Yasuo Morisima; Yoshihisa Kodera; Shunichi Kato
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 7.  Endocrinopathies in Inborn Errors of Immunity.

Authors:  Kei Takasawa; Hirokazu Kanegane; Kenichi Kashimada; Tomohiro Morio
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

8.  Gonadal failure among female patients after hematopoietic stem cell transplantation for non-malignant diseases.

Authors:  Akito Sutani; Yuichi Miyakawa; Atsumi Tsuji-Hosokawa; Risa Nomura; Ryuichi Nakagawa; Keisuke Nakajima; Mitsue Maru; Yuki Aoki; Kei Takasawa; Masatoshi Takagi; Kohsuke Imai; Kenichi Kashimada; Tomohiro Morio
Journal:  Clin Pediatr Endocrinol       Date:  2019-10-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.